U.S. Markets close in 4 hrs 45 mins

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.9388-2.6412 (-6.5086%)
As of 11:14AM EDT. Market open.
People also watch
Full screen
Previous Close40.5800
Bid38.7000 x 500
Ask39.3000 x 100
Day's Range35.3901 - 40.9999
52 Week Range5.0000 - 51.9000
Avg. Volume70,642
Market Cap76.89M
PE Ratio (TTM)14.27
EPS (TTM)2.66
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.67
Trade prices are not sourced from all markets
  • GlobeNewswire4 hours ago

    Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis

    SANTA MONICA, Calif., Sept. 25, 2017-- Opiant Pharmaceuticals, Inc.,, today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on ...

  • Forbes5 days ago

    Opiant Up Nearly 30% On Favorable Zacks Report

    Opiant Pharmaceuticals jumped nearly 30% yesterday on a favorable report from Zacks, making it the forth largest position in Todd Hagopian's Biotech Fund. Here's what Todd thinks of the news.

  • Zacks Small Cap Research6 days ago

    OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant

    On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. On August 10, 2017, Opiant announced an additional $3.75 million payment from SWK related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording $25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017.